(FMTX) – FDA
-
Forma Therapeutics Holdings (FMTX) Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline
-
Forma Therapeutics' (FMTX) Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 AML
-
-
-
-
-
-
-
-
Back to FMTX Stock Lookup